Acne News and Research

Latest Acne News and Research

New Alma’s Soprano laser technology delivers painless procedure for hair removal

Alma Lasers, Ltd., a leader in laser, light, radiofrequency and ultrasound-based aesthetic devices, unveils the latest in next generation medical laser technology with the debut of its new Soprano(XLi) for laser hair removal and deep dermal heating.

12 Nov 2010

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

9 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

30 Oct 2010

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

The Providence (R.I.) Journal: "The Lifespan hospital group and Blue Cross have reached an agreement intended to gradually overturn the way hospital care is financed, with the goal of promoting health, rather than episodes of treatment. The agreement is the first to meet unique-in-the-nation rules from state Health Insurance Commissioner Christopher F. Koller, who has identified hospital costs as the main reason for increases in health-insurance premiums.

30 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

First Edition: October 27, 2010

Today's headlines note that the new health law has Democrats playing defense, while Republicans offer few new alternatives to the sweeping measure.

27 Oct 2010

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2010.

27 Oct 2010

Stress can literally show up on the face

According to an Australian stylist stress affects the health as well as appearance. Gregory Landsman, the author of Face and Fitness said that high stress level is immediately visible on a person’s face.

26 Oct 2010

Syneron launches VelaBABE device for women to reclaim pre-baby body

Syneron Medical Ltd., a leading medical aesthetic device innovator, is announcing their new VelaBABE promotion for women who want to reclaim their pre-baby body with help from VelaShape.

19 Oct 2010

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

NovaBay Pharmaceuticals, Inc. announced today that its development partner, Alcon Research, Ltd., has concluded its proof of concept clinical trial of NovaBay's patented lead Aganocide compound, NVC-422 for the treatment of viral conjunctivitis a highly contagious eye infection for which there are currently no marketed products.

18 Oct 2010

Solta Medical announces acquisition of CLRS Technology

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced it has acquired privately-held CLRS Technology, a provider of personal care solutions based in Costa Mesa, California.

18 Oct 2010

Coalition for At-Risk Youth helps foster children improve self-esteem

There is no denying that teenagers in the foster care system need special support so they can begin to develop the skills that will take them successfully into adulthood. Those with skin, hair or nail diseases may face even more challenges because their self-esteem may have been shattered by the obvious signs of their condition.

14 Oct 2010

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Researchers from NanoBio Corporation and the University of Michigan Medical School today announced the receipt of a $1.5 million grant from the Department of Defense (DoD) to study the use of nanoemulsion-based therapies for protection against burn and wound infections.

13 Oct 2010

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono, a division of Merck KGaA, Darmstadt, Germany has announced that new data presented today at the 35th Congress of the European Society for Medical Oncology (ESMO) have shown that patients with KRAS wild-type metastatic colorectal cancer (mCRC) who experienced early tumor shrinkage (within 8 weeks) during 1st line Erbitux (cetuximab) based treatment lived a median of 28.3 months.

12 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Suneva Medical publishes Artefill data for treatment of atrophic acne scars

Suneva Medical, a privately-held aesthetic medical device company, today announced the publication of an open-label, single center, pilot study on Artefill for the treatment of atrophic acne scars conducted by James M. Spencer, M.D. M.S. and sponsored by Suneva Medical.

8 Oct 2010

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Cipher Pharmaceuticals Inc. today announced that the U.S. Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-TRAMADOL ER, the Company's extended-release tramadol product for the treatment of moderate to moderately severe chronic pain in adults.

8 Oct 2010

Acne News and Research

Latest Acne News and Research

New Alma’s Soprano laser technology delivers painless procedure for hair removal

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Cipher announces completion of patient enrolment in CIP-ISOTRETINOIN Phase III study for nodular acne

State Watch: R.I. group experiments with payment reform; Ariz. dispute over abortion; Vt. and Feds to end monitoring of caregivers

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

First Edition: October 27, 2010

Cipher reports net revenue of $1.1 million for 2010 third quarter

Stress can literally show up on the face

Syneron launches VelaBABE device for women to reclaim pre-baby body

Alcon concludes 'proof of concept' clinical trial of NovaBay's Aganocide for viral conjunctivitis treatment

Solta Medical announces acquisition of CLRS Technology

Coalition for At-Risk Youth helps foster children improve self-esteem

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Erbitux-based therapy helps in early tumor shrinkage, long-term survival in mCRC patients with KRAS wild-type tumors

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Suneva Medical publishes Artefill data for treatment of atrophic acne scars

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Acne News and Research

Latest Acne News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in